BER loaded nanoformulations directed for intranasal administration have been previously reported in several studies
Again, the overlap complicates assessment
A phase II trial in GHD adults (n=32) reported IGF-1 normalization in 5075% of participants at 30120 g/kg monthly, which was observed to be comparable to daily GH therapy [pubmed.ncbi.nlm.nih.gov]
Adverse CV manifestations exist in 8%25% of the overall COVID-19-infected population and this percentage is even higher among intensive care unit (ICU) and non-survival patients ( 2 Clinical manifestation The incidence of LC is estimated at 10%30% of non-hospitalized cases, 50%70% of hospitalized cases, and 10%12% of vaccinated cases (Table 1) ( Table 1 Selected clinical manifestations of long COVID [according to ( Symptoms after COVID-19 infection are wide-ranging and often include persistent cardiac symptoms ( There are many theories regarding the cause of LC, however, the causes are likely multifactorial and potentially overlapping, including ongoing viral infection (viral persistence), which contributes to ongoing inflammation and immune response, immune system dysregulation, with or without reactivation of latent viruses (including herpesviruses such as EpsteinBarr virus and human herpesvirus 6), microthrombi (micro-clots), endothelial dysfunction (ED), microbiota dysbiosis, systemic fibrosis, autoimmunity, and autonomic dysfunction ( COVID-19 patients may present with non-specific symptoms, such as dyspnea and fatigue that may have a cardiac origin ( Cardiovascular complications have been described in the acute phase of COVID-19
Apart from improvements in multiple cardiometabolic risk factors, tirzepatide also improves various obesity-related complications such as obstructive sleep apnoea (OSA), metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction [2830]
